3-dimensional Pharmaceuticals, Inc.

Janssen Pharmaceutica Nv

Wenxi Pan

Tianbao Lu

Bruce Edward Tomczuk

Thomas P Markotan

Jeremy Mark Travins

Mark James Wall

Sanath K Meegalla

Mark R Player

Kristi A Leonard

Jinsheng Chen

Maxwell David Cummings

Shelley K Ballentine

Hui Huang

Nalin L Subasinghe

Heather Rae Hufnagel

Ehab Khalil

Farah Ali

Yu-Kai Lee

Joan Gushue

William H Parsons

Scott L Dax

Richard M Soll

Mark Andrew Youngman

Daniel J Parks

Kenneth M Wells

Michele C Jetter

Kenneth J Wilson

Karen L Milkiewicz

M Jonathan Rudolph

Raul R Calvo

Tho V Thieu

Wing S Cheung

Sharmila Patel

Jian Liu

Michael Richard Brandt

Derek A Beauchamp

Jonathan Rudolph

Kenneth T Wilson

Raul L Calvo

Michael Brandt

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.

Benzimidazole modulators of VR1

The present invention is directed to novel compounds of Formula I: and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.

Factor Xa compounds

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R, R, R, Rand Rare defined in the specification, Z is SO or SO, and Ar is an aromatic or heteroaromatic group as defined herein. 

Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R, R, R, Rand Rare defined in the specification, Z is SO or SO, and Ar is an aromatic or heteroaromatic group as defined herein.

Phenyl acetamide compounds are described, including compounds ofor a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R-R, R, B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Aminopyridyl-substituted phenyl acetamides as protease inhibitors

Aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors

Heteroaryl protease inhibitors and diagnostic imaging agents

Growing community of inventors

Glenmore, PA, United States of America

Wenxi Pan